Ohio State Navbar

Research

Other Extramural Funding


 

Lauren Bakaletz, PhD 01/01/16-12/31/18 Australian Govt National Health and Medicla Research Council
Novel Epigenetic Regulatory Mechanisms in Moraxella Catarrhalis and Non-typeable Haemophilus Influenzae: Impact on Vaccine Development and Role in Pathobiology APP1099279
 

 

Tendy Chiang, MD 05/01/2016-04/30/2017 The Ohio State University Center for Clinical and Translational Science Davis Bremer Pre-K Award
Clinical Translation of Novel Bioartificial Tissue Engineered Tracheal Grafts
 

 

Tendy Chiang, MD 12/01/2015-11/30/2016 The Ohio State University Center for Clinical and Translational Science Longitudinal Pilot Award
The Ohio State University Center for Clinical and Translational Science Longitudinal Pilot Award
 

 

Kris R. Jatana, MD

02/2015 - Present Technology Development Fund Grant
Development of new surgical safety devices
Goal is to develop devices to improve surgical safety during otolaryngology surgery.

 

Kris R. Jatana, MD 04/25/2011 - Present Technology Development Fund Grant
Improving the tracheostomy tube care
The goal of this study is to study is to develop improved tracheostomy tube care for both children and adults.

 

Pawan Kumar, PhD
(PI of Correlative Studies)
12/18/13-12/17/17 NCCN Clinical Trial
Phase I/II clinical trial of sorafenib in combination with cisplatin and docetaxel in patients with recurrent/metastatic squamous cell carcinoma of the head and neck
 

 

Aaron Moberly, MD 2016 American Otological Society Clinician-Scientist Award
Variability in Speech Recognition for Adults with Cochlear Implants
 

 

Aaron Moberly, MD 08/01/2014-07/31/2016 Triological Society Career Development Award
Personalizing Aural Rehabilitation for Adults with Cochlear Implants
 

 

Aaron Moberly, MD 2014 - Present Triological Society Career Development Award, AAO-HNS CORE grant
Personalizing Aural Rehabilitation for Adults with Cochlear Implants
 

 

Matthew Old, MD 01/2013-Present OSUCCC Viral Oncology Program Research Award
Enhancement of oncolytic herpes virus (34.5ENVE) activity in head and neck squamous cell carcinoma with bortezomib